Phase I clinical trials are an essential step in the development of anticancer drugs. The main
goal of these studies is to establish the recommended dose and/or schedule of new drugs or …

Modern oncology drug development faces challenges very different from those of the past
and it must adapt accordingly. The size and expense of phase III clinical trials continue to …

Prior Knowledge Elicitation: The Past, Present, and Future Page 1 Bayesian Analysis (2024)
19, Number 4, pp. 1129–1161 Prior Knowledge Elicitation: The Past, Present, and Future ∗ …

Optimal Design for Nonlinear Response Models discusses the theory and applications of
model-based experimental design with a strong emphasis on biopharmaceutical studies …

The Bayesian approach to finding the maximum‐tolerated dose in phase I cancer trials is
discussed. The suggested approach relies on a realistic dose–toxicity model, allows one to …

We present a definition for the effective sample size of a parametric prior distribution in a
Bayesian model, and propose methods for computing the effective sample size in a variety …

Bayesian Designs for Phase I–II Clinical Trials Page 1 Page 2 Ying Yuan The University of
Texas MD Anderson Cancer Center Houston, Texas, USA Hoang Q. Nguyen The University of …

Adaptive designs for clinical trials permit alterations to a study in response to accumulating
data in order to make trials more flexible, ethical, and efficient. These benefits are achieved …

Much of the statistical methodology underlying the experimental design of phase 1 trials in
oncology is intended for studies involving a single cytotoxic agent. The goal of these studies …

A balanced treatment of the theories, methodologies, and design issues involved in clinical
trials using statistical methods There has been enormous interest and development in …